Page 1

Demographics / Basic Info

| Record ID | |
|---|---|
| Center Name | |
| Local Identifier (how the patient is coded at the center, please do not use medical record numbers. Instead, please assign a patient a code that you can then refer to if specific questions arise) | |
| Age at Surgery (years) | |
| Sex | ○ Male○ Female○ Non-Binary |
| Race / Decent | Unavailable White African / African American Asian - Southern Asian - East Asian - Central Asian - Russia Asian Southeastern Middle (Asian Western) Eastern Pacific Islander American Indian Hispanic / Latin American Aboriginal |
| BMI at OR | |
| Historical BMI (1 year prior to OR) | |
| Penicillin Allergy? | |
| History of Myocardial Infarction / Coronary Artery Disease | ○ No ○ Yes |
| History of Congestive Heart Failure | ○ No ○ Yes |
| History of Peripheral Vascular Disease | ○ No ○ Yes |
| History of Stroke or TIA | ○ No ○ Transient Ischemic Attack or Stroke without Hemiplegia ○ Stroke with Hemiplegia |

projectredcap.org **REDCap**®

| History of Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Restrictive Lung Disease or other Chronic Pulmonary Disease (not cancer) | ○ No ○ Yes |
|--|--|
| Hx of Dementia or other Mental Handicap | ○ No ○ Yes |
| Chronic Connective Tissue / Rheumatic Disease | ○ No ○ Yes |
| Hx of Peptic Ulcer Disease | ○ No ○ Yes |
| Hx of Cancer (not skin cancer except for metastatic melanoma) | ○ No○ Yes, Localized○ Yes, Metastatic |
| Hx of Chronic Liver Disease | No Hepatitis C (treated or untreated or cirrhosis without portal hypertension Severe cirrhosis, portal hypertension, or history of bleed |
| Hx of Diabetes Mellitus (Type 1 or 2) | No Yes, no end-organ damage Yes, end-organ damage but not neuropathy (ie. retinopathy, nephropathy) |
| Hx of Moderate to Severe CKD (Dialysis, Uremia, Creatinine > 3) | ○ No ○ Yes |
| AIDS Diagnosis (not just HIV positive) | ○ No ○ Yes |
| Hx of Leukemia | ○ No ○ Yes |
| Hx of Lymphoma | ○ No ○ Yes |
| Charlson Comorbidity Score | |
| Age-Adjusted Charlson Comorbidity Index | |



Pre-Operative Labs

| Pre-Operative WBC | |
|---|---|
| | |
| Pre-Operative Hgb | |
| , | |
| | |
| Pre-Operative Hct | |
| | |
| Pre-Operative Plt | |
| · | |
| | |
| Pre-Operative Absolute Neutrophil Count | |
| | |
| Pre-Operative Absolute Lymphocyte Count | |
| | |
| | |
| Creatinine | |
| | |
| Pre-Operative Albumin | |
| The operative Albahim | |
| | |
| Pre-Operative PT | |
| | |
| Pre-Operative PTT | |
| rie-Operative riii | |
| | • |
| Pre-Operative INR | |
| | |

REDCap°

02/08/2023 10:21am

Tumor Characteristics

| Laterality | ○ left ○ right |
|----------------------------------|--|
| Bone/soft tissue sarcoma or met? | ○ Bone○ Soft tissue○ Metastasis from non-bone or soft tissue sarcoma |
| Type of sarcoma of bone | Chondrosarcoma Periosteal chondrosarcoma Clear cell chondrosarcoma Mesenchymal chondrosarcoma Dedifferentiated chondrosarcoma Low grade chondrosarcoma High grade chondrosarcoma Surface chondrosarcoma Low Grade Central Osteosarcoma Conventional Osteosarcoma Telangiectatic Osteosarcoma Small Cell Osteosarcoma Parosteal Osteosarcoma Pariosteal Osteosarcoma Periosteal Osteosarcoma Periosteal Osteosarcoma Secondary Osteosarcoma Secondary Osteosarcoma Secondary Osteosarcoma Secondary Osteosarcoma Chondroblastic Osteosarcoma Well differentiated Osteosarcoma Dedifferentiated Osteosarcoma Epithelioid Haemangioendothelioma Angiosarcoma GCT of Bone Chordoma Poorly Differentiated Chordoma Dedifferentiated Chordoma Dedifferentiated Chordoma Dedifferentiated Chordoma Dedifferentiated Pleomorphic Sarcoma) Plasmacytoma of Bone Lymphoma Langerhans Cell Histiocytosis Ewing sarcoma Atypical Cartilaginous Tumor Chondroma Bone cyst |

□ **R**EDCap°

| Type of soft tissue sarcoma | Liposarcoma Dedifferentiated Liposarcoma Myxoid Liposarcoma Pleomorphic / Epithelioid Liposarcoma Myxoid Pleomorphic Liposarcoma Solitary Fibrous Tumor Fibrosarcoma Myxofibrosarcoma Low-Grade Fibromyxoid Sarcoma Sclerosing Epithelioid Fibrosarcoma Malignant Tenosynovial Giant Cell Tumor Epithelioid Haemangioendothelioma Angiosarcoma Glomus Tumor Leiomyosarcoma Embryonal Rhabdomyosarcoma Alveolar Rhabdomyosarcoma Pleomorphic Rhabdomyosarcoma Extraskeletal Osteosarcoma Extraskeletal Osteosarcoma Extraskeletal Osteosarcoma Malignant Peripheral Nerve Sheath Tumor Melanotic Malignant Peripheral Nerve Sheath Tumor Granlar Cell Tumor Perineurioma Phosphaturic Mesenchymal Tumor Synovial Sarcoma, Spindle Cell Synovial Sarcoma, Poorly Differentiated Epithelioid Sarcoma Alveolar Soft Part Sarcoma Clear Cell Sarcoma Extraskeletal Myxoid Chondrosarcoma Desmoplastic Small Round Cell Tumor Rhabdoid Tumor Perivascular Epithelioid Tumor Intimal Sarcoma Ossifying Fibromyxoid Tumor Myoepithelioid Carcinoma Undifferentiated Sarcoma Spindle Cell Sarcoma, Undifferentiated Pleomorphic Sarcoma, Undifferentiated Round Cell Sarcoma, Undifferentiated Round Cell Sarcoma, Undifferentiated |
|----------------------------------|--|
| Type of Metastatic Disease | ○ Thyroid○ Renal Cell○ Breast○ Lung○ Prostate○ Other |
| "Other" Metastatic Disease | |
| Subtype of Breast Adenocarcinoma | ○ Invasive Ductal Carcinoma○ Invasive Lobular Carcinoma○ Mixed○ Paget's / Inflammatory○ Other |
| "Other" Breast Pathology | |

| Breast Primary Tumor Hormone Status (check all that are positive, or unknown if hormone status is unknown) | ☐ Estrogen☐ Progesterone☐ Her-2 Neu☐ Unknown |
|---|--|
| Breast Metastatic Disease Hormone Status (check all that are positive, or unknown if hormone status is unknown) | ☐ Estrogen ☐ Progesterone ☐ Her-2 Neu ☐ Unknown |
| History of Tamoxifen during primary tumor treatment? | ○ Yes ○ No |
| Femur Involvement? | No Intra-articular / femoral involvement via primary tumor extension Distant met to femur |
| Tumor Size (cm) | |
| | ((Largest dimension)) |
| Pathologic Fracture | ○ Yes ○ No |
| Bone Sarcoma Type | Appendicular skeleton, trunk, skull and facial bonesSpinePelvis |
| Soft Tissue Sarcoma Type | Trunk or extremity Retroperitoneum Head and Neck Abdomen and thoracic visceral organs |
| Bone Primary Tumor Characteristic | No evidence of primary tumor (T0) The main tumor is no more than 8 centimeters across (T1) The main tumor is more than 8 centimeters across (T2) Discontinuous tumors in the primary bone site (T3) Primary tumor cannot be assessed |
| Bone Sarcoma Lymph Node Spread | No regional lymph node metastasis Regional lymph nodes metastasis Regional lymph node cannot be assessed |
| Bone Sarcoma Metastatic Disease | ○ No distant metastasis (M0) ○ Lung only distant metastasis (M1a) ○ Bone or other distant sites (M1b) |
| Bone Sarcoma Grade | Well differentiated, low grade (G1) Moderately differentiated, high grade (G2) Poorly differentiated, high grade (G3) The grade cannot be determined (GX) |

| Soft Tissue Sarcoma Primary Tumor | No evidence of primary tumor (T0) Tumor 5 cm or less in greatest dimension (T1) Tumor more than 5 cm and ≤10 cm in greatest dimension (T2) Tumor more than 10 cm and ≤15 cm in greatest dimension (T3) Tumor more than 15 cm in greatest dimension (T4) Primary tumor cannot be assessed (TX) |
|--|--|
| Soft Tissue Sarcoma Lymph Node Spread | No regional lymph node metastasis or unknown lymph node status Regional lymph nodes metastasis |
| Soft Tissue Sarcoma Metastatic Disease | ○ No distant metastasis (M0)○ Distant metastasis (M1) |
| Soft Tissue Sarcoma Histologic Characteristics | Sarcoma closely resembling normal adult mesenchymal tissue Sarcomas for which histologic typing is certain Embryonal and undifferentiated sarcomas, sarcomas of doubtful type, and synovial sarcomas |
| Soft Tissue Sarcoma Mitotic Activity | ○ 0-9 mitoses per 10 HPF○ 10-19 mitoses per 10 HPF○ ≥20 mitoses per 10 HPF |
| Soft Tissue Sarcoma Necrosis | No necrosis< 50% tumor necrosis≥50% tumor necrosis |

Oncologic Treatment Hx

| History of Hormone Therapy? | ○ No○ Anastrazole○ Testosterone Blockers○ Herceptin |
|--|--|
| Neoadjuvant Chemo? | Yes No No |
| Type of Neoadjuvant Chemo (check all that were given as neoadjuvant therapy) | ☐ Cytotoxic ☐ Immunotherapy ☐ Hormone therapy ☐ Other |
| "Other" Neoadjuvant chemo | |
| Adjuvant Chemo? | ○ Yes ○ No |
| Type of Adjuvant Chemo (check all that were given as neoadjuvant therapy) | ☐ Cytotoxic ☐ Immunotherapy ☐ Hormone therapy ☐ Other |
| "Other" Adjuvant chemo | |
| Neoadjuvant Radiation? | ○ Yes ○ No |
| Neoadjuvant Rads Dose (Gy) | |
| Date of Completion of Neoadj Rads | |
| Adjuvant Radiation? | ○ Yes ○ No |
| Adjuvant Rads Dose (Gy) | - <u></u> |
| Date of adjuvant rads treatment start | |

₹EDCap°

Surgical Treatment

| Date of Diagnosis (D-M-Y) | | |
|---|---|--|
| Date of Surgery (D-M-Y) | | |
| Primary or Revision Procedure? | ○ Primary○ Revision | |
| Reconstruction Performed | ○ Intercalary Reconstruction ○ Osteoarticular Allograft ○ Hemicondylar Allograft ○ Alloprosthetic Composite ○ Arthrodesis ○ Rotationplasty ○ Endoprosthesis ○ Hemiintercalary Allograft ○ Custom-made Implant | |
| Extensor Mechanism Reconstruction | ○ None○ Alloprosthesis○ Gastrocnemius○ Bone to metal○ Soft tissue to metal | |
| Antibiotics Used | ○ Cephalosporin○ Vancomycin○ Tobramycin○ Clindamycin○ Combination○ "Other" | |
| What Combination of Antibiotics? | | |
| What "Other" antibiotic was used? | | |
| Duration of IV antibiotics post-operatively (days) | | |
| Duration of PO antibiotics after surgery (days, please write "0" if no orals were used) | | |
| Topical antibiotic powder used? | ○ None○ Cephalosporin○ Vancomycin○ Tobramycin○ Combination | |
| What combination of topical antibiotic powder was used? | | |
| Providone iodine soak performed after implant placement | ○ Yes ○ No | |

• REDCap

| Drain placed? (one or more) | |
|--|---|
| Duration of Procedure (Hours) | |
| Estimated Blood Loss (cc) | |
| Resection length (from joint to cut, cm) | |
| Intra-articular or Extra-articular Resection? | ○ Intra-articular○ Extra-articular |
| Planned Margins | ○ Wide (> 1 cm)○ Marginal (< 1 cm)○ Planned Micro+○ Planned Macro+ |
| Actual Margins | ○ R0 ○ R1 ○ R2 |
| Closure | Primary Skin graft without a flap Flap (rotational) Flap (muscle rotational) + skin graft Free flap |
| Tubercle Sparing? (Maintenance of the anterolateral tibial cortex including the tibial tubercle in continuity with the distal native bone) | |
| Patella resurfaced? | ○ Yes ○ No |
| Patellar tendon reconstructed? | ○ Yes ○ No |
| Estimated or measured % of length of resected patellar tendon available for reconstruction (100% = tendon preserved completely, 0% = complete resection) | |
| How much patellar tendon was able to be repaired/reconstructed? | |
| Did the tendon reach the tendon attachment site? | ○ Yes ○ No |
| Was an augment used to extend the residual patellar tendon? | ○ Yes ○ No |

| How was the patellar tendon re-attached? | Suture aloneSuture + synthetic tendon augmentEndoprosthesis built-in tendon |
|--|---|
| Proximal fibula resected? | ○ Yes ○ No |
| Anterior tibial artery resected? | ○ Yes ○ No |
| Posterior tibial artery resected | YesNo |
| Common peroneal nerve resected | |
| Tibial nerve resected? | ○ Yes○ No |
| Vascularized fibula graft | YesNo |
| Vascularized fibula graft with allograft (Capanna technique) | ○ Yes ○ No |
| DVT prophylaxis used post-op? | None ASA 81 daily ASA 81 twice a day ASA 325 daily Lovenox 40 mg daily Lovenox 30 mg twice a day Subcutaneous heparin Coumadin DOAC (oral anticoagulant such as rivaroxaban) Other |
| "Other" DVT prophylaxis used | |

Endoprosthesis Characteristics

| Endoprosthesis used | Depuy / J&J Zimmer / Biomet Stryker MUTARS LNK Onkos Smith & Nephew Stanmore "Other" |
|---|--|
| Endoprosthesis coating | NoneSilverlodineUnsure |
| Lengthening endoprosthesis? | ○ No○ Yes - Growing |
| Type of lengthening | Minimally invasive lengthening (non-surgical)Invasive lengthening (surgical) |
| Type of knee mechanism | ○ Rotating hinge○ Fixed hinge |
| Cemented or Non-Cemented Tibia? | ○ Cemented○ Non-cemented (press-fit) |
| Cement Used for Tibia? | ○ Antibiotic○ Non-antibiotic |
| Type of antibiotic cement used for tibia | ○ Cephalosporin○ Vancomycin○ Tobramycin○ Gentamycin○ Combination |
| "Combination" antibiotic cement for tibia | |
| Cemented or non-cemented femur? | ○ Cemented○ Non-cemented (press fit) |
| Cement used for femur? | AntibioticNon-antibiotic |
| Type of antibiotic cement used for femur | CephalosporinVancomycinTobramycinGentamycinCombination |
| "Combination" antibiotic cement femur | |

02/08/2023 10:21am projectredcap.org **REDCap***

Allograft/APC/Rotationplasty Characteristics

| Mode of stabilization | ○ Non-locking plate○ Locking plate○ Nail and locking plate○ Nail and non-locking plate○ Other |
|--|---|
| "Other" mode of stabilization | |
| How many plates crossed the distal junction | ○ 1○ 2○ Plate(s) augmented with a nail |
| How many plates crossed the proximal junction? | ○ 1○ 2○ Plate(s) augmented by a nail |
| Time from rotationplasty to prosthesis fitting (days) | |
| Vessel resection with tumor and re-anastomosis vs. coiling required? | |

₹EDCap°

Complications

| Has this limb salvage experienced a mechanical or non-mechanical complication? | Yes No |
|--|--|
| How many mechanical or non-mechanical complications occurred? | |
| Date of Complication #1 (Day-Month-Year) | |
| Complication #1 Henderson Type | Mechanical IA - Soft Tissue Failure - Instability due to Tendon/Muscle Rupture Mechanical IB - Soft Tissue Failure - Aseptic Wound Dehiscence Mechanical IIA - Aseptic Loosening - < 2 Years after Implantation Mechanical IIB - Aseptic Loosening - > 2 Years after Implantation Mechanical Allograft II - Nonunion Mechanical IIIA - Structural Failure - Prosthetic Failure Mechanical IIIB - Structural Failure - Periprosthetic Failure Mechanical Allograft III - Structural failure - Allograft Fracture Non-Mechanical IVA - Periprosthetic Infection - < 2 Years after Implantation Non-Mechanical IVA - Allograft Infection - < 6 Months after Implantation Non-Mechanical IVA - Allograft Infection - > 6 Months after Implantation Non-Mechanical VA - Tumor Progression with Contamination of Prosthesis - Soft Tissue Tumor Non-Mechanical VB - Tumor Progression with Contamination of Prosthesis - Bone Tumor |
| Infectious pathogen | No Growth Gram + Bacteria Gram - Bacteria Polymicrobial Bacteria Fungal alone Mycobacterial Polymicrobial (fungal + bacteria) |
| How was complication #1 managed? | None Supportive OR with implant retention OR with exchange of PE components OR with partial retention of metallic components OR with complete implant exchange Amputation Rotationplasty Ongoing failure management Allograft revision to prosthesis |
| Date of Complication #2 (Day-Month-Year) | |

p.org **REDCap**°

| Complication #2 Henderson Type | Mechanical IA - Soft Tissue Failure - Instability due to Tendon/Muscle Rupture Mechanical IB - Soft Tissue Failure - Aseptic Wound Dehiscence Mechanical IIA - Aseptic Loosening - < 2 Years after Implantation Mechanical IIB - Aseptic Loosening - > 2 Years after Implantation Mechanical Allograft II - Nonunion Mechanical Allograft III - Nonunion Mechanical IIIB - Structural Failure - Prosthetic Failure Mechanical IIIB - Structural Failure - Periprosthetic Failure Mechanical Allograft III - Structural failure - Allograft Fracture Non-Mechanical IVA - Periprosthetic Infection - < 2 Years after Implantation Non-Mechanical IVB - Periprosthetic Infection - > 2 Years after Implantation Non-Mechanical IVA - Allograft Infection - > 6 Months after Implantation Non-Mechanical IVA - Tumor Progression with Contamination of Prosthesis - Soft Tissue Tumor Non-Mechanical VB - Tumor Progression with Contamination of Prosthesis - Bone Tumor |
|--|--|
| Infectious pathogen | ○ No Growth ○ Gram + Bacteria ○ Gram - Bacteria ○ Polymicrobial Bacteria ○ Fungal alone ○ Mycobacterial ○ Polymicrobial (fungal + bacteria) |
| How was complication #2 managed? | None Supportive OR with implant retention OR with exchange of PE components OR with partial retention of metallic components OR with complete implant exchange Amputation Rotationplasty Ongoing failure management Allograft revision to prosthesis |
| Date of Complication #3 (Day-Month-Year) | |

| Complication #3 Henderson Type | Mechanical IA - Soft Tissue Failure - Instability due to Tendon/Muscle Rupture Mechanical IB - Soft Tissue Failure - Aseptic Wound Dehiscence Mechanical IIA - Aseptic Loosening - < 2 Years after Implantation Mechanical IIB - Aseptic Loosening - > 2 Years after Implantation Mechanical Allograft II - Nonunion Mechanical IIIA - Structural Failure - Prosthetic Failure Mechanical IIIB - Structural Failure - Periprosthetic Failure Mechanical Allograft III - Structural failure - Allograft Fracture Non-Mechanical IVA - Periprosthetic Infection - < 2 Years after Implantation Non-Mechanical IVA - Allograft Infection - < 6 Months after Implantation Non-Mechanical IVA - Allograft Infection - > 6 Months after Implantation Non-Mechanical VA - Tumor Progression with Contamination of Prosthesis - Soft Tissue Tumor Non-Mechanical VB - Tumor Progression with Contamination of Prosthesis - Bone Tumor |
|--|--|
| Infectious pathogen | No Growth Gram + Bacteria Gram - Bacteria Polymicrobial Bacteria Fungal alone Mycobacterial Polymicrobial (fungal + bacteria) |
| How was complication #3 managed? | None Supportive OR with implant retention OR with exchange of PE components OR with partial retention of metallic components OR with complete implant exchange Amputation Rotationplasty Ongoing failure management Allograft revision to prosthesis |
| Date of Complication #4 (Day-Month-Year) | |
| | |

02/08/2023 10:21am

| Complication #4 Henderson Type | Mechanical IA - Soft Tissue Failure - Instability due to Tendon/Muscle Rupture Mechanical IB - Soft Tissue Failure - Aseptic Wound Dehiscence Mechanical IIA - Aseptic Loosening - < 2 Years after Implantation Mechanical IIB - Aseptic Loosening - > 2 Years after Implantation Mechanical Allograft II - Nonunion Mechanical IIIA - Structural Failure - Prosthetic Failure Mechanical IIIB - Structural Failure - Periprosthetic Failure Mechanical Allograft III - Structural failure - Allograft Fracture Non-Mechanical IVA - Periprosthetic Infection - < 2 Years after Implantation Non-Mechanical IVB - Periprosthetic Infection - > 2 Years after Implantation Non-Mechanical IVA - Allograft Infection - < 6 Months after Implantation Non-Mechanical IVA - Allograft Infection - > 6 Months after Implantation Non-Mechanical IVA - Tumor Progression with Contamination of Prosthesis - Soft Tissue Tumor Non-Mechanical VB - Tumor Progression with Contamination of Prosthesis - Bone Tumor |
|--|--|
| Infectious pathogen | No Growth Gram + Bacteria Gram - Bacteria Polymicrobial Bacteria Fungal alone Mycobacterial Polymicrobial (fungal + bacteria) |
| How was complication #4 managed? | None Supportive OR with implant retention OR with exchange of PE components OR with partial retention of metallic components OR with complete implant exchange Amputation Rotationplasty Ongoing failure management Allograft revision to prosthesis |
| Date of Complication #5 (Day-Month-Year) | |
| | |

| Complication #5 Henderson Type | Mechanical IA - Soft Tissue Failure - Instability due to Tendon/Muscle Rupture Mechanical IB - Soft Tissue Failure - Aseptic | | |
|---------------------------------------|---|--|--|
| | Wound Dehiscence ○ Mechanical IIA - Aseptic Loosening - < 2 Years | | |
| | after Implantation | | |
| | Mechanical IIB - Aseptic Loosening - > 2 Years | | |
| | after Implantation | | |
| | Mechanical Allograft II - Nonunion Machanical IIIA - Structural Failure - Brasthetic | | |
| | Mechanical IIIA - Structural Failure - Prosthetic Failure | | |
| | Mechanical IIIB - Structural Failure - | | |
| | Periprosthetic Failure Machanical Allegraft III Structural failure | | |
| | Mechanical Allograft III - Structural failure - Allograft Fracture | | |
| | Non-Mechanical IVA - Periprosthetic Infection - <2 Years after Implantation | | |
| | Non-Mechanical IVB - Periprosthetic Infection - >2 Years after Implantation | | |
| | Non-Mechanical IVA - Allograft Infection - < 6 | | |
| | Months after Implantation | | |
| | ○ Non-Mechanical IVA - Allograft Infection - > 6 | | |
| | Months after Implantation | | |
| | Non-Mechanical VA - Tumor Progression with Contamination of Prosthesis - Soft Tissue Tumor | | |
| | Non-Mechanical VB - Tumor Progression with | | |
| | Contamination of Prosthesis - Bone Tumor | | |
| Infectious pathogen | O No Growth | | |
| , , | Gram + Bacteria | | |
| | ○ Gram - Bacteria | | |
| | Polymicrobial BacteriaFungal alone | | |
| | Mycobacterial | | |
| | O Polymicrobial (fungal + bacteria) | | |
| How was complication #5 managed? | ○ None | | |
| | Supportive | | |
| | OR with implant retention | | |
| | OR with exchange of PE components OR with partial retention of metallic components | | |
| | OR with complete implant exchange | | |
| | Amputation | | |
| | Rotationplasty | | |
| | Ongoing failure management | | |
| | Allograft revision to prosthesis | | |
| Any other complications + management? | | | |
| | | | |
| Was there a 90-day Readmission? | ○ No | | |
| | Yes - Medical (non-surgical reason) | | |
| | Yes - Surgical (surgical or medical complication directly related to OR) | | |
| Amputation required? | | | |
| | ○ No | | |
| | | | |

| Reason for amputation | ○ Infection○ Fracture○ Implant failure○ Pain○ Functional Deficit | |
|--------------------------------------|--|--|
| Date of amputation (D-M-Y) | | |
| Failure (re-operation or amputation) | ○ Yes ○ No | |
| Deceased? | ○ No○ Yes - tumor related○ Yes - non-tumor related | |
| Date deceased | | |

Oncologic Outcomes

| Local recurrence? | ○ Yes ○ No | |
|------------------------------------|---------------|--|
| Date of local recurrence (M-D-Y) | | |
| Distant recurrence? | ○ Yes ○ No | |
| Date of distant recurrence (D-M-Y) | | |

₹EDCap°

Mobility

| Date of max follow-up | |
|--|--|
| Follow up time in months | |
| Knee extension at most recent follow-up | Full 1-5 deg lag 6-10 deg lag 11-15 deg lag > 15 deg lag |
| Knee flexion at most recent follow-up | <pre>< 45 deg 45-90 deg 91-120 deg 121-150 deg > 150 deg</pre> |
| Strength in extension (0-5 scale) | ○ 0○ 1○ 2○ 3○ 4○ 5 |
| Strength in flexion | ○ 0○ 1○ 2○ 3○ 4○ 5 |
| Range of Motion (degrees) | |
| Valgus stability at full extension | 0-5 mm opening 6-10 mm opening > 10 mm opening or the lack of any firm endpoint |
| Valgus stability at 30 deg of flexion | 0-5 mm opening 6-10 mm opening > 10 mm opening or the lack of any firm endpoint |
| Varus stability at full extension | 0-5 mm opening 6-10 mm opening > 10 mm opening or the lack of any firm endpoint |
| Varus stability at 30 deg of flexion | 0-5 mm opening on valgus stress 6-10 mm opening on valgus stress > 10 mm opening or the lack of any firm endpoint |
| Firm endpoint on anterior/posterior translation of knee at 0 deg | |

02/08/2023 10:21am projectredcap.org REDCap®

| Firm endpoint of anterior and posterior translation of the knee in 30 deg flex | |
|--|---|
| At max follow-up, patient's primary (>50%) mode of support | None Brace Cane 1 Crutch 2 Crutches Walker Minimal/Non-Ambulator |
| Gait at max follow-up | Normal Minor Cosmetic abnl Major Cosmetic abnl Minor Functional abnl Major Functional abnl Could not ambulate post-op (but could pre-op) |
| Single episode no-rest walking capacity at max follow-up | UnlimitedCommunity AmbulatorLimited in-home ambulationUnable to ambulate |

Patient-Reported Outcomes

| Pre-Op PROMIS Physical Function score | |
|---|--|
| PROMIS Physical Function Score 1-Year after Primary PTR | |
| Date of Max PROMIS Physical Function Score (D-M-Y) | |
| PROMIS Physical Function Score at Max Follow-Up | |
| Pre-Op PROMIS Pain Interference Score | |
| PROMIS Pain Interference Score 1-Year After Primary PTR | |
| Date of Max PROMIS Pain Interference Score (D-M-Y) | |
| PROMIS Pain Interference Score at Max Follow-Up | |
| Pre-Op PROMIS Depression Score | |
| PROMIS Depression Score 1-Year after Primary PTR | |
| Date of Max PROMIS Depression Score (D-M-Y) | |
| PROMIS Depression Score at Max Follow-Up | |
| Pre-Op PROMIS Anxiety Score | |
| PROMIS Anxiety Score 1-Year after Primary PTR | |
| Date of Max PROMIS Anxiety Score (D-M-Y) | |
| PROMIS Anxiety Score at Max Follow-Up | |
| Pre-Op PROMIS Social Disability Score | |

₹EDCap°

projectredcap.org

02/08/2023 10:21am

| PROMIS Social Disability Score 1-Year after Primary PTR | |
|---|--|
| Date of Max PROMIS Social Disability Score (D-M-Y) | |
| PROMIS Social Disability Score at Max Follow-Up | |
| Pre-Op SF-12 Score | |
| SF-12 Score 1-Year after Primary PTR | |
| Date of Max SF-12 (D-M-Y) | |
| SF-12 Score at Max Follow-Up | |
| Pre-Op EQ50 Score | |
| EQ50 Score at 1-Year Follow-Up | |
| Date of Max EQ50 (D-M-Y) | |
| EQ50 Score at Max Follow-Up | |
| Pre-Op MSTS Score | |
| MSTS Score 1-Year after Primary PTR | |
| Date of Max MSTS Score (D-M-Y) | |
| MSTS Score at Max Follow-Up | |
| Pre-Op TESS Score | |
| TESS Score 1-Year after Primary PTR | |
| Date of Max TESS Score (D-M-Y) | |



TESS Score at Max Follow-Up



X-ray Records

| Where available, please upload X-ray images (in image picture form, such as jpeg) as requested below. Where possible, please include the FULL implant where available |
|---|
| Pre-Operative AP Knee X-ray |
| Pre-Operative Lateral Knee X-ray |
| 4-6 Week Post-Op AP Knee X-ray |
| 4-6 Week Post-Op Lateral Knee X-ray |
| 3 Month Post-Op AP Knee X-ray |
| 3 Month Post-Op Lateral Knee X-ray |
| 6 Month Post-Op AP Knee X-ray |
| 6 Month Post-Op Lateral Knee X-ray |
| 1-Year Post-Op AP Knee X-ray |
| 1-Year Post-Op Lateral Knee X-ray |
| 2-Year Post-Op AP Knee X-ray |
| 2-Year Post-Op Lateral Knee X-ray |
| Date of Max Follow-Up X-ray |
| Max Follow-Up AP Knee X-ray |



02/08/2023 10:21am

Max Follow-Up Lateral Knee X-ray

Patient Summary

| Summary/Additional comments: | |
|--|--|
| Describe in free text a summary of the patient to | |
| explain multiple revisions, course or add any comments | |

